by Elizabeth Matsui and Roger Peng
The controversy over Theranos and the quality of its diagnostic tests continues to unfold. But a larger issue is being played ou, which is that there are unique challenges faced by health tech startups. In particular, health tech startups need to both produce a product that people want to buy and also develop a product that is scientifically valid. An article in the Wall Street Journal challenged the scientific credibility of Theranos’s tests and the jury is still out on that question.
Elizabeth and I discussed various aspects of this story and the implications for health tech startups. You can listen to our conversation here.